Human | MYOCD | 93649 | myocardin | data suggest that functional natural myocardin promoter variation might be a genetic factor contributing to inter-individual differences in the development of cardiac hypertrophy |
Human | TFB2M | 64216 | transcription factor B2, mitochondrial | determined the variation in the TFAM, TFB1M, and TFB2M genes in cardiac hypertrophy |
Human | MYOZ2 | 51778 | myozenin 2 | Two missense mutations, S48P substitution and I246M affecting highly conserved amino acids were linked to hereditary Hypertrophic cardiomyopathy characterized by early onset of symptoms, pronounced cardiac hypertrophy, and cardiac arrhythmias |
Human | PRKAG2 | 51422 | protein kinase, AMP-activated, gamma 2 non-catalytic subunit | The AMP kinase disease is uncommon in HCM and is characterized by progressive conduction disease and cardiac hypertrophy and includes extracardiac manifestations such as a skeletal myopathy |
Human | TFB1M | 51106 | transcription factor B1, mitochondrial | determined the variation in the TFAM, TFB1M, and TFB2M genes in cardiac hypertrophy |
Human | IFT81 | 28981 | intraflagellar transport 81 homolog (Chlamydomonas) | inconsistent expression levels of human CDV-1 and mouse Cdv-1 in heart implied that cardiac hypertrophy in human SCD might not be associated with the abnormal expression of CDV-1 |
Human | LATS2 | 26524 | large tumor suppressor kinase 2 | Lats2 affects both growth and death of cardiac myocytes, but it primarily regulates the size of the heart and acts as an endogenous negative regulator of cardiac hypertrophy |
Human | YWHAQ | 10971 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide | In transgenic mice with cardiac specific overexpression of dominant negative 14-3-3 protein, 14-3-3 negatively regulates cardiac hypertrophy and fibrosis, possibly through controlling expression of protein kinase C beta 2 in the diabetic myocardium |
Human | CORIN | 10699 | corin, serine peptidase | corin gene single nucleotide polymorphism associated with hypertension and cardiac hypertrophy impair corin zymogen activation and natriuretic peptide processing activity Corin I555(P568) allele represents a cardiac hypertrophy-sensitizing genetic locus in systemic hypertension |
Human | HCN4 | 10021 | hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | down-regulation of miR-1 and miR-133 expression contributes to re-expression of HCN2/HCN4 and thereby the electrical remodeling process in hypertrophic hearts |
Human | AKT3 | 10000 | v-akt murine thymoma viral oncogene homolog 3 | activation of Akt signaling results in progression from adaptive to maladaptive cardiac hypertrophy |
Human | HDAC4 | 9759 | histone deacetylase 4 | HDAC4 as a specific downstream substrate of CaMKIIdeltaB in cardiac cells and have broad applications for the signaling pathways leading to cardiac hypertrophy and heart failure |
Human | VCL | 7414 | vinculin | cardiac hypertrophy may be associated with different expression of the marker vinculin/metavinculin depending on the underlying pathophysiology |
Human | TP53 | 7157 | tumor protein p53 | Induced the transition from cardiac hypertrophy to heart failure through the suppression of hypoxia inducible factor-1(HIF-1), which regulates angiogenesis in the hypertrophied heart and promotes apoptosis |
Human | TNNT2 | 7139 | troponin T type 2 (cardiac) | spectrum of mutations in cardiac hypertrophy patients |
Human | TNNI3 | 7137 | troponin I type 3 (cardiac) | the TNNI3 Pro82Ser alteration is likely a disease-modifying mutation in a severely affected individual, and, furthermore, carriers of this alteration (3% of African Americans) might be at increased risk of late-onset cardiac hypertrophy spectrum of mutations in cardiac hypertrophy patients |
Human | THRB | 7068 | thyroid hormone receptor, beta | Except for cardiac hypertrophy, the presence of a germline TR-beta mutation had surprisingly little effect on cardiac function |
Human | TFAM | 7019 | transcription factor A, mitochondrial | determined the variation in the TFAM, TFB1M, and TFB2M genes in cardiac hypertrophy |
Human | STK11 | 6794 | serine/threonine kinase 11 | Increased transsfected LKB1 activity in the cardiac myocyte can decrease hypertrophy-induced protein synthesis and suggest that LKB1 activation may be a method for the prevention of pathological cardiac hypertrophy |
Human | SLC9A1 | 6548 | solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 | Activation of NHE1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure Enhanced activity of the cardiac Na+/H+ exchanger (NHE-1) after myocardial stretch is considered a key step of the signaling pathway leading to cardiac hypertrophy[REVIEW] |
Human | RRAD | 6236 | Ras-related associated with diabetes | Rad is a novel mediator that inhibits cardiac hypertrophy through the CaMKII pathway |
Human | REN | 5972 | renin | Prorenin-induced stimulation of p38 MAPK/HSP27 pathway, resulting in alterations in actin filament dynamics, may underlie severe cardiac hypertrophy previously seen in rats with hepatic prorenin overexpression |
Human | MAPK3 | 5595 | mitogen-activated protein kinase 3 | Specific phosphorylation events on ERK1/2 integrate differing upstream signals to induce cardiac hypertrophy |
Human | PPP3CB | 5532 | protein phosphatase 3, catalytic subunit, beta isozyme | depressed NCX activity might contribute to the etiology of in vivo cardiac hypertrophy and dysfunction occurring under conditions in which both calcineurin and protein kinase C are chronically activated |
Human | PPARA | 5465 | peroxisome proliferator-activated receptor alpha | decrease in cardiac PPARalpha transcription factor gene expression observed in the failing human heart could play an important role in a reduction in fatty acid utilisation by the adult heart during cardiac hypertrophy |